Development of antigen multimers for detection and evaluation of CAR T cells
Cancer Immunology, Immunotherapy · 23.10.2025 · 74 (11)
DOI: 10.1007/s00262-025-04134-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 23.10.2025. Verfasst von Rasmus U W Friis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, T-Lymphocytes, Immunotherapy, Adoptive, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carlsbergfondet, Danmarks Frie Forskningsfond, Novo Nordisk Fonden.
Abstract (Originalsprache)
Background
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of hematologic cancers by engineering T cells to specifically target and destroy cancer cells. Monitoring CAR T cell activity and function is essential for optimizing therapeutic outcomes, but existing tools for CAR detection are often limited in specificity and functional assessment capability.
Methods
We developed dextran multimers by conjugating multiple CAR-specific antigens to a dextran backbone. The multimers were compared to previously reported antigen tetramers for their ability to stain and detect CAR T cells. Because these multimers incorporate the CAR target antigen, they uniquely enable assessment of CAR T cell functionality. We tested the staining and functional properties of the multimers across a range of CAR constructs with different affinities, using flow cytometry and microscopy.
Results
The dextran multimers demonstrated high specificity and sensitivity in staining CAR T cells, with adjustable antigen density to optimize binding. Dextran multimers also enabled effective clustering and subsequent activation of CARs, showing their utility as both a staining and functional assessment tool. The multimers revealed that CARs with different affinities and clustering tendencies displayed varied binding and activation in response to different antigen densities.
Conclusion
Dextran multimers offer a dual advantage as versatile reagents for both staining and functional analysis of CAR T cells. Their capacity to engage CARs with the specific antigen provides a valuable platform for evaluating CAR functionality, informing CAR design improvements, and enhancing therapeutic precision.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.
- Division of Genetic Immunotherapy, Leibniz Institute for Immunotherapy, Regensburg, Germany.
- Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark. sirha@dtu.dk.
Förderung
- Carlsbergfondet
- Danmarks Frie Forskningsfond
- Novo Nordisk Fonden
- Bioneer
- Kirsten og Freddy Johansens Fond
- Technical University of Denmark
Zitieren
APA
Friis, R. U. W., Ormhøj, M., Krüger-Jensen, C. S., Pardo, C. R., Halldórsdóttir, H. R., Barden, M., Kristensen, N. P., Ramanathan, K., Hansen, M. R., Abken, H., & Hadrup, S. R. (2025). Development of antigen multimers for detection and evaluation of CAR T cells. Cancer Immunology, Immunotherapy, 74(11). https://doi.org/10.1007/s00262-025-04134-9
Vancouver
Friis RUW, Ormhøj M, Krüger-Jensen CS, Pardo CR, Halldórsdóttir HR, Barden M, et al. Development of antigen multimers for detection and evaluation of CAR T cells. Cancer Immunology, Immunotherapy. 2025;74(11). doi:10.1007/s00262-025-04134-9
BibTeX
@article{Friis2025,
author = {Friis, Rasmus U W and Ormhøj, Maria and Krüger-Jensen, Cecilie S and Pardo, Carlos Rodriguez and Halldórsdóttir, Hólmfridur Rósa and Barden, Markus and Kristensen, Nikolaj P and Ramanathan, Keerthana and Hansen, Mikkel R and Abken, Hinrich and Hadrup, Sine R},
title = {Development of antigen multimers for detection and evaluation of CAR T cells},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {11},
doi = {10.1007/s00262-025-04134-9}
}
EUVIMED